DOCSLIB.ORG

Human Herpesvirus-6, Varicella-Zoster Virus and Oligoclonal Bands in Demyelinating Diseases of the Central Nervous System

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Human Herpesvirus-6, Varicella-Zoster Virus and Oligoclonal Bands in Demyelinating Diseases of the Central Nervous System Human herpesvirus-6, varicella-zoster virus and oligoclonal bands in demyelinating diseases of the central nervous system Jenna Nicklén Doctoral Programme in Clinical Research Department of Virology, Haartman Institute, Medicum Department of Neurology, Clinicum Faculty of Medicine University of Helsinki Finland ACADEMIC DISSERTATION To be presented for public examination, with permission of the Faculty of Medicine of the University of Helsinki on 18th March 2016, at noon Supervisor Professor Markus Färkkilä Department of Neurology, Clinicum Faculty of Medicine University of Helsinki Reviewers Docent Merja Soilu-Hänninen Department of Neurology Faculty of Medicine University of Turku Docent Veijo Hukkanen Department of Virology Faculty of Medicine University of Turku Official Opponent Professor Irina Elovaara Department of Neurology Faculty of Medicine University of Tampere ISBN 978-951-51-1910-0 (paperback) ISBN 978-951-51-1911-7 (PDF) http://ethesis.helsinki.fi Unigrafia Oy, Helsinki 2016 TABLE OF CONTENTS LIST OF ORIGINAL PUBLICATIONS .................................................................................................... 5 ABBREVIATIONS ................................................................................................................................ 6 ABSTRACT ......................................................................................................................................... 8 TIIVISTELMÄ .................................................................................................................................... 10 INTRODUCTION .............................................................................................................................. 12 1 LITERATURE REVIEW ............................................................................................................... 14 1.1 HUMAN HERPESVIRUS-6 (HHV-6) .................................................................................... 14 1.1.1 Introduction of the virus .......................................................................................... 14 1.1.2 Characteristic features ............................................................................................. 15 1.1.3 Clinical significance in adults .................................................................................... 16 1.1.4 Diagnostic tools for diagnosing HHV-6 infection in the CNS .................................... 17 1.1.5 HHV-6 and demyelinating diseases .......................................................................... 18 1.1.6 HHV-6 in other neurological diseases ...................................................................... 19 1.1.7 Antiviral treatment of HHV-6 ................................................................................... 20 1.1.8 Radiological features in HHV-6 encephalopathy...................................................... 21 1.2 VARICELLA-ZOSTER VIRUS ............................................................................................... 22 1.2.1 Introduction and characteristic features of the virus .............................................. 22 1.2.2 Clinical significance in adults .................................................................................... 25 1.2.3 Diagnostic tools for diagnosing VZV infection in CNS .............................................. 25 1.2.4 VZV and demyelinating diseases .............................................................................. 26 1.2.5 Antiviral treatment and prevention of VZV ............................................................. 26 1.3 MULTIPLE SCLEROSIS ....................................................................................................... 27 1.3.1 Introduction and clinical characteristics of MS ........................................................ 27 1.3.2 Pathogenesis of MS .................................................................................................. 29 1.3.2.1 Cell-mediated autoimmunity theory of MS ......................................................... 30 1.3.2.2 Humoral autoimmunity theory of MS .................................................................. 30 1.3.2.3 Viral theories of MS pathogenesis ........................................................................ 31 1.3.3 Treatment of MS ...................................................................................................... 31 1.4 OLIGOCLONAL BANDS ..................................................................................................... 33 1.4.1 Introduction of OCBs ................................................................................................ 33 1.4.2 OCBs in clinical use ................................................................................................... 34 1.4.3 OCBs in neurological diseases .................................................................................. 34 1.4.4 OCBs reactivity against different pathogens ............................................................ 35 2 AIMS OF THE STUDY ................................................................................................................ 36 3 PATIENTS AND METHODS ....................................................................................................... 37 3.1 PATIENTS .......................................................................................................................... 37 3.1.1 Patients (I-V) ............................................................................................................. 37 3.1.2 Samples (I-V) ............................................................................................................. 37 3.1.3 Ethical approval ........................................................................................................ 38 3.2 METHODS ......................................................................................................................... 38 3.2.1 Antibody tests of HHV-6A and HHV-6B (I-IV) ........................................................... 38 3.2.2 Avidity test (I-IV) ....................................................................................................... 38 3.2.3 OCB detection (II-V) .................................................................................................. 38 3.2.4 HHV-6 and VZV-reactivity in OCBs (II-V) ................................................................... 39 3.2.5 Clinical data (I-V) ...................................................................................................... 39 3.2.6 Neurological diagnoses (I-V)..................................................................................... 40 3.2.7 Statistical analysis (III, V, thesis) ............................................................................... 40 4 RESULTS ................................................................................................................................... 41 4.1 HHV-6 SEROLOGICAL PRIMARY INFECTION AND MS (I, III, IV) ...................................... 41 4.2 VIRUS-REACTIVE OCBS (II-V) .......................................................................................... 44 5 DISCUSSION ............................................................................................................................. 49 5.1 SEROLOGICALLY CONFIRMED HHV-6 IN MS .................................................................... 49 5.2 VIRUS-REACTIVE OCBS IN MS .......................................................................................... 51 5.2.1 Total number of OCB ................................................................................................ 52 5.2.2 How can the small number of virus-reactive OCBs be explained, when compared to the total number of OCBs? ..................................................................................................... 54 5.2.3 Virus-reactive OCBs; polyclonal activation or antibody production against relevant antigens? ................................................................................................................................. 54 5.3 MECHANISMS FOR HOW HHV-6 AND VZV COULD BE INVOLVED IN DEMYELINATION AND MS PATHOGENESIS ............................................................................................................. 55 5.3.1 Cell-mediated and humoral autoimmunity theories of MS ..................................... 55 5.3.1.1 Molecular mimicry ................................................................................................ 55 5.3.1.2 Interaction with leukocytes .................................................................................. 55 5.3.2 Direct virus infection of the CNS .............................................................................. 56 5.3.3 Gives access to other pathogens to infect the host CNS? ....................................... 57 6 CONCLUSIONS AND FUTURE ASPECTS .................................................................................... 58 ACKNOWLEDGEMENTS .................................................................................................................. 59 REFERENCES ................................................................................................................................... 61 SUPPLEMENT “Potilaskaavake” LIST OF ORIGINAL PUBLICATIONS I Pietiläinen J, Virtanen JO, Uotila L, Salonen O, Koskiniemi M and Färkkilä M. HHV-6 infection in multiple sclerosis.
Load more

Recommended publications
  • Impact of Human Cytomegalovirus and Human Herpesvirus 6 Infection
    International Journal of Molecular Sciences Article Impact of Human Cytomegalovirus and Human Herpesvirus 6 Infection on the Expression of Factors Associated with Cell Fibrosis and Apoptosis: Clues for Implication in Systemic Sclerosis Development Maria-Cristina Arcangeletti 1,*, Maria D’Accolti 2 , Clara Maccari 1, Irene Soffritti 2 , Flora De Conto 1, Carlo Chezzi 1, Adriana Calderaro 1, Clodoveo Ferri 3 and Elisabetta Caselli 2 1 Department of Medicine and Surgery, Unit of Virology, University-Hospital of Parma, University of Parma, 43126 Parma, Italy; [email protected] (C.M.); fl[email protected] (F.D.C.); [email protected] (C.C.); [email protected] (A.C.) 2 Department of Chemical and Pharmaceutical Sciences, Section of Microbiology and Medical Genetics, University of Ferrara, 44121 Ferrara, Italy; [email protected] (M.D.); irene.soff[email protected] (I.S.); [email protected] (E.C.) 3 Department of Medical and Surgical Sciences for Children and Adults, Rheumatology Unit, University-Hospital Policlinico of Modena, University of Modena and Reggio Emilia, 41121 Modena, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-0521-033497 Received: 29 July 2020; Accepted: 31 August 2020; Published: 3 September 2020 Abstract: Systemic sclerosis (SSc) is a severe autoimmune disorder characterized by vasculopathy and multi-organ fibrosis; its etiology and pathogenesis are still largely unknown. Herpesvirus infections, particularly by human cytomegalovirus (HCMV) and human herpesvirus 6 (HHV-6), have been suggested among triggers of the disease based on virological and immunological observations. However, the direct impact of HCMV and/or HHV-6 infection on cell fibrosis and apoptosis at the cell microenvironment level has not yet been clarified.
    [Show full text]
  • Human Herpesvirus 6 in Cerebrospinal Fluid of Patients Infected with HIV
    J Neurol Neurosurg Psychiatry 1999;67:789–792 789 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.67.6.789 on 1 December 1999. Downloaded from SHORT REPORT Human herpesvirus 6 in cerebrospinal fluid of patients infected with HIV: frequency and clinical significance Simona Bossolasco, Roberta Marenzi, Helena Dahl, Luca Vago, Maria Rosa Terreni, Francesco Broccolo, Adriano Lazzarin, Annika Linde, Paola Cinque Abstract convulsions or other neurological symptoms The objective was to evaluate the fre- complicating exanthema subitum.2–4 HHV-6 quency of human herpesvirus 6 (HHV-6) encephalitis or milder neurological symptoms DNA detection in the CSF of patients have been described in both immunocompet- infected with HIV and its relation to brain ent adults and transplanted patients,5–7 and the disease and systemic HHV-6 infection. virus might also play an aetiological part in Nested polymerase chain reaction multiple sclerosis.8 HHV-6 has also been found (PCR) was used to analyse CSF samples in the brain or CSF of adults and children with from 365 consecutive HIV infected pa- AIDS, but its role in neurological disease is still tients with neurological symptoms. When unclear.9–12 available, plasma and brain tissues from To study the possible relation between patients whose CSF was HHV-6 positive HHV-6 and brain disease in patients infected were also studied. with HIV, the presence of HHV-6-DNA in the HHV-6 was found in the CSF of eight of CSF was assessed in a large group of patients copyright. Division of Infectious the 365 patients (2.2%): two had type A with neurological disease and was correlated Diseases, San RaVaele and four type B; the HHV-6 variant could with clinical and neuropathology patterns.
    [Show full text]
  • But Significantly Different From, Human Herpesvirus 6 and Human Cytomegalovirus (Chronic Fatigue Syndrome/T Lymphocytes) Zwi N
    Proc. Natd. Acad. Sci. USA Vol. 89, pp. 10552-10556, November 1992 Medical Sciences Human herpesvirus 7 is a T-lymphotropic virus and is related to, but significantly different from, human herpesvirus 6 and human cytomegalovirus (chronic fatigue syndrome/T lymphocytes) Zwi N. BERNEMAN*, DHARAM V. ABLASHIt, GE LI*, MAUREEN EGER-FLETCHER*, MARVIN S. REITZ, JR.*, CHIA-LING HUNGO§, IRENA BRUS¶, ANTHONY L. KOMAROFFII, AND ROBERT C. GALLO*,** *Laboratory of Tumor Cell Biology and tLaboratory of Cellular and Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; TPharmacia, Columbia, MD 21045; NMount Sinai School of Medicine, New York, NY 10029; and IlDepartment of Internal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115 Communicated by Maurice Hilleman, August 6, 1992 ABSTRACT An independent strain (JI) of human herpes- for 1-2 hr at 370C with virus-containing culture supernatant. virus 7 (HV-7) was isolated from a patient with chronic Afterward, the cell lines were cultured in RPMI 1640 medi- fatigue syndrome (CFS). No s cant association could be um/2-10%o fetal calf serum, whereas the CBMC were grown established by seroepidemiology between HHV-7 and CFS. in RPMI 1640 medium/5-20%o fetal calf serum with or with- HHV-7 is a T-lymphotropic virus, infecting CD4+ and CD8+ out 10% (vol/vol) interleukin 2 (Advanced Biotechnologies, primary lymphocytes. HHV-7 can also infect SUP-T1, an Columbia, MD). Infection was assessed by the appearance of immature T-cell line, with variable success. Southern blot large cells, immunofluorescence, and EM.
    [Show full text]
  • Clinical Impact of Primary Infection with Roseoloviruses
    Available online at www.sciencedirect.com ScienceDirect Clinical impact of primary infection with roseoloviruses 1 2 1 Brenda L Tesini , Leon G Epstein and Mary T Caserta The roseoloviruses, human herpesvirus-6A -6B and -7 (HHV- infection in different cell types, have the ability to reac- 6A, HHV-6B and HHV-7) cause acute infection, establish tivate, and may be intermittently shed in bodily fluids [3]. latency, and in the case of HHV-6A and HHV-6B, whole virus Unlike other human herpesviruses, HHV-6A and HHV- can integrate into the host chromosome. Primary infection with 6B are also found integrated into the host genome HHV-6B occurs in nearly all children and was first linked to the (ciHHV-6). Integration has been documented in 0.2– clinical syndrome roseola infantum. However, roseolovirus 1% of the general population and along with latency infection results in a spectrum of clinical disease, ranging from has confounded the ability to correlate the presence of asymptomatic infection to acute febrile illnesses with severe viral nucleic acid with active disease [4]. neurologic complications and accounts for a significant portion of healthcare utilization by young children. Recent advances The syndrome known as roseola infantum was reported as have underscored the association of HHV-6B and HHV-7 early as 1809 by Robert Willan in his textbook ‘On primary infection with febrile status epilepticus as well as the cutaneous diseases’ [5]. This clinical entity is also com- role of reactivation of latent infection in encephalitis following monly referred to as exanthem subitum and early pub- cord blood stem cell transplantation.
    [Show full text]
  • Cytomegalovirus, Human Herpesvirus 6, and Bacteriophage T4 DNA Polymerases (Antibody/Viral Enzyme) CHING-HWA ANN TSAI*, MARSHALL V
    Proc. Nati. Acad. Sci. USA Vol. 87, pp. 7963-7%7, October 1990 Medical Sciences A monoclonal antibody that neutralizes Epstein-Barr virus, human cytomegalovirus, human herpesvirus 6, and bacteriophage T4 DNA polymerases (antibody/viral enzyme) CHING-HWA ANN TSAI*, MARSHALL V. WILLIAMS*t, AND RONALD GLASER*tt *Department of Medical Microbiology and Immunology, and tComprehensive Cancer Center, The Ohio State University Medical Center, Columbus, OH 43210 Communicated by Leo A. Paquette, July 23, 1990 (received for review May 18, 1990) ABSTRACT A monoclonal antibody (mAb) designated DNA polymerase activity (20), it is not known whether this 55H3 was produced by using chemically induced Epstein-Barr polyclonal antibody neutralizes the DNA polymerase activity virus genome-positive B95-8 cells. mAb 55H3, which reacted by binding to the enzyme or due to its binding to one of the with an 85- to 80-kDa polypeptide, neutralized Epstein-Barr associated polypeptides. Thus, further studies on the inter- virus-encoded DNA polymerase activity in crude extracts of actions of these polypeptides have been hampered, in part, chemically induced M-ABA, HR-1, and B95-8 cells, as well as from the lack of specific antibodies against the EBV-encoded the partially purified Epstein-Barr virus DNA polymerase in a DNA polymerase. dose-dependent manner. The mAb also neutralized the virus- Recently, we reported the isolation of an EBV-specific encoded DNA polymerase activity from cells infected with monoclonal antibody (mAb), designated 55H3, that neutral- human cytomegalovirus, human herpesvirus 6, and the puri- izes the activity of EBV-encoded DNA polymerase (21). In fied bacteriophage T4 DNA polymerases.
    [Show full text]
  • The Development of New Therapies for Human Herpesvirus 6
    Available online at www.sciencedirect.com ScienceDirect The development of new therapies for human herpesvirus 6 2 1 Mark N Prichard and Richard J Whitley Human herpesvirus 6 (HHV-6) infections are typically mild and data from viruses are generally analyzed together and in rare cases can result in encephalitis. A common theme reported simply as HHV-6 infections. Here, we will among all the herpesviruses, however, is the reactivation upon specify the specific virus where possible and will simply immune suppression. HHV-6 commonly reactivates in use the HHV-6 designation where it is not. Primary transplant recipients. No therapies are approved currently for infection with HHV-6B has been shown to be the cause the treatment of these infections, although small studies and of exanthem subitum (roseola) in infants [4], and can also individual case reports have reported intermittent success with result in an infectious mononucleosis-like illness in adults drugs such as cidofovir, ganciclovir, and foscarnet. In addition [5]. Infections caused by HHV-6A and HHV-7 have not to the current experimental therapies, many other compounds been well characterized and are typically reported in the have been reported to inhibit HHV-6 in cell culture with varying transplant setting [6,7]. Serologic studies indicated that degrees of efficacy. Recent advances in the development of most people become infected with HHV-6 by the age of new small molecule inhibitors of HHV-6 will be reviewed with two, most likely through saliva transmission [8]. The regard to their efficacy and spectrum of antiviral activity. The receptors for HHV-6A and HHV-6B have been identified potential for new therapies for HHV-6 infections will also be as CD46 and CD134, respectively [9,10].
    [Show full text]
  • Human Herpesvirus-6 and -7 in the Brain Microenvironment of Persons with Neurological Pathology and Healthy People
    International Journal of Molecular Sciences Article Human Herpesvirus-6 and -7 in the Brain Microenvironment of Persons with Neurological Pathology and Healthy People Sandra Skuja 1,* , Simons Svirskis 2 and Modra Murovska 2 1 Institute of Anatomy and Anthropology, R¯ıga Stradin, š University, Kronvalda blvd 9, LV-1010 R¯ıga, Latvia 2 Institute of Microbiology and Virology, R¯ıga Stradin, š University, Ratsup¯ ¯ıtes str. 5, LV-1067 R¯ıga, Latvia; [email protected] (S.S.); [email protected] (M.M.) * Correspondence: [email protected]; Tel.: +371-673-20421 Abstract: During persistent human beta-herpesvirus (HHV) infection, clinical manifestations may not appear. However, the lifelong influence of HHV is often associated with pathological changes in the central nervous system. Herein, we evaluated possible associations between immunoexpression of HHV-6, -7, and cellular immune response across different brain regions. The study aimed to explore HHV-6, -7 infection within the cortical lobes in cases of unspecified encephalopathy (UEP) and nonpathological conditions. We confirmed the presence of viral DNA by nPCR and viral antigens by immunohistochemistry. Overall, we have shown a significant increase (p < 0.001) of HHV antigen expression, especially HHV-7 in the temporal gray matter. Although HHV-infected neurons were found notably in the case of HHV-7, our observations suggest that higher (p < 0.001) cell tropism is associated with glial and endothelial cells in both UEP group and controls. HHV-6, predominantly detected in oligodendrocytes (p < 0.001), and HHV-7, predominantly detected in both astrocytes and oligodendrocytes (p < 0.001), exhibit varying effects on neural homeostasis.
    [Show full text]
  • Persistent Infection with Human Herpesvirus-6 in Patients with an Inherited Form of the Virus
    University of South Florida Scholar Commons Graduate Theses and Dissertations Graduate School January 2013 Persistent Infection with Human Herpesvirus-6 in Patients with an Inherited Form of the Virus: A Newly Described Disease Shara Pantry University of South Florida, [email protected] Follow this and additional works at: http://scholarcommons.usf.edu/etd Part of the Virology Commons Scholar Commons Citation Pantry, Shara, "Persistent Infection with Human Herpesvirus-6 in Patients with an Inherited Form of the Virus: A Newly Described Disease" (2013). Graduate Theses and Dissertations. http://scholarcommons.usf.edu/etd/4928 This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact [email protected]. Persistent Human Herpesvirus-6 Infection in Patients with an Inherited Form of the Virus: a Newly Described Disease by Shara N. Pantry A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Department of Molecular Medicine College of Medicine University of South Florida Major Professor: Peter G. Medveczky, M.D. George Blanck, Ph.D. Gloria Ferreira, Ph.D. Ed Seto, Ph.D. Date of Approval November 5, 2013 Keywords: HHV-6, Chronic Fatigue Syndrome, Inherited Herpesvirus Syndrome, Virus Integration, Telomere Copyright © 2013, Shara N. Pantry DEDICATION I dedicate this dissertation to my grandparents, Ladric and Retinella Lewis, my parents, Beverley and Everard Pantry, and to my brothers, Marlondale and Lamonte Pantry. I would also like to dedicate this dissertation, to my niece and nephew, Chaniah and Marlondale Pantry.
    [Show full text]
  • Herpesviral Latency—Common Themes
    pathogens Review Herpesviral Latency—Common Themes Magdalena Weidner-Glunde * , Ewa Kruminis-Kaszkiel and Mamata Savanagouder Department of Reproductive Immunology and Pathology, Institute of Animal Reproduction and Food Research of Polish Academy of Sciences, Tuwima Str. 10, 10-748 Olsztyn, Poland; [email protected] (E.K.-K.); [email protected] (M.S.) * Correspondence: [email protected] Received: 22 January 2020; Accepted: 14 February 2020; Published: 15 February 2020 Abstract: Latency establishment is the hallmark feature of herpesviruses, a group of viruses, of which nine are known to infect humans. They have co-evolved alongside their hosts, and mastered manipulation of cellular pathways and tweaking various processes to their advantage. As a result, they are very well adapted to persistence. The members of the three subfamilies belonging to the family Herpesviridae differ with regard to cell tropism, target cells for the latent reservoir, and characteristics of the infection. The mechanisms governing the latent state also seem quite different. Our knowledge about latency is most complete for the gammaherpesviruses due to previously missing adequate latency models for the alpha and beta-herpesviruses. Nevertheless, with advances in cell biology and the availability of appropriate cell-culture and animal models, the common features of the latency in the different subfamilies began to emerge. Three criteria have been set forth to define latency and differentiate it from persistent or abortive infection: 1) persistence of the viral genome, 2) limited viral gene expression with no viral particle production, and 3) the ability to reactivate to a lytic cycle. This review discusses these criteria for each of the subfamilies and highlights the common strategies adopted by herpesviruses to establish latency.
    [Show full text]
  • Human Herpesvirus-6 Infections
    98 Dollery 22 Kirkpatrick CJ. Microcirculatory problems in multiple organ failure: the role 29 Levy M, Benson LN, Burrows PE, et al. Tissue plasminogen activator for of endotoxins and particulate contamination. In: Lee HA, Barnet MI, eds. the treatment ofthromboembolism in infants and children. JPediatr 1991; Proceedings of the symposium on managing the complications of intravenous 118: 467-72. Arch Dis Child: first published as 10.1136/adc.74.2.98 on 1 February 1996. Downloaded from therapy. Portsmouth: Pall Biomedical, 1993: 5-13. 30 Rodenhuis S, van't Hek LGFM, Vlasveld T, Kroger R, Dubbelman R, van 23 Bamett MI, Coslett AG, Cohen J. Filtration of lipid containing total par- Tol RGL. Central venous catheter associated thrombosis of major veins: enteral nutrition (TPN) admixtures [Abstract]. Clinical Nutrition 1995; 14 thrombolytic treatment with recombinant tissue plasminogen activator. (suppl 2): 49. Thorax 1993; 48: 558-9. 24 Andrew M, Marzinotto V, Massicotte P, et al. Heparin therapy in pediatric 31 Farfel Z, Shechter M, Vered Z, et al. Review of echocardiographically diag- patients: a prospective cohort study. Pediatr Res 1994; 35: 78-83. nosed right heart entrapment ofpulmonary emboli-in-transit with empha- 25 Hirsh J, van Aken WG, Gallus AS, Dollery CT, Cade JF, Yung WL. sis on management. Am HeartJ 1986; 113: 171-8. Heparin kinetics in venous thrombosis and pulmonary embolism. 32 Cameron J, Pohner PG, Stafford EG, et al. Right heart thrombus: recogni- Circulation 1976; 53: 691-5. tion, diagnosis, and management. J Am Coll Cardiol 1985; 5: 1239-43. 26 Owens JP, Mirtallo JM, Murphy CC.
    [Show full text]
  • Characterization of Higher Order Chromatin Structures and Chromatin States in Cell Models of Human Herpesvirus Infection
    University of Vermont UVM ScholarWorks Graduate College Dissertations and Theses Dissertations and Theses 2021 Characterization Of Higher Order Chromatin Structures And Chromatin States In Cell Models Of Human Herpesvirus Infection Michael Mariani University of Vermont Follow this and additional works at: https://scholarworks.uvm.edu/graddis Part of the Biology Commons, Genetics and Genomics Commons, and the Virology Commons Recommended Citation Mariani, Michael, "Characterization Of Higher Order Chromatin Structures And Chromatin States In Cell Models Of Human Herpesvirus Infection" (2021). Graduate College Dissertations and Theses. 1424. https://scholarworks.uvm.edu/graddis/1424 This Dissertation is brought to you for free and open access by the Dissertations and Theses at UVM ScholarWorks. It has been accepted for inclusion in Graduate College Dissertations and Theses by an authorized administrator of UVM ScholarWorks. For more information, please contact [email protected]. CHARACTERIZATION OF HIGHER ORDER CHROMATIN STRUCTURES AND CHROMATIN STATES IN CELL MODELS OF HUMAN HERPESVIRUS INFECTION A Dissertation Presented by Michael Mariani to The Faculty of the Graduate College of The University of Vermont In Partial Fulfilment of the Requirements For the Degree of Doctor of Philosophy Specializing in Cellular, Molecular, and Biomedical Sciences May, 2021 Defense Date: March 24, 2021 Dissertation Examination Committee: Seth Frietze, Ph.D., Advisor Matthew Poynter, Ph.D., Chairperson David Pederson Ph.D. Stephen Keller Ph.D. Cynthia J. Forehand, Ph.D., Dean of the Graduate College COPYRIGHT © Copyright by Michael Mariani May 2021 ABSTRACT Human herpesviruses are ubiquitous pathogens worldwide with 90% of the global population infected with one or more Human herpesviruses (HHV’s) by adulthood.
    [Show full text]
  • Herpesvirus Infections of the Central Nervous System
    Publisher: Thieme; Journal: SIN; Article Type: Review Article Journal ISSN: 0271-8235; Article ID Number: SIN-18-0092 Volume Number: 39; Issue Number: 3 1Department of Biochemistry, University of Oxford, London, United Kingdom 2Laos-Oxford-Mahosot Hospital Wellcome Trust Research Unit, Mahosot Hospital, Vientiane, Laos, United Kingdom 3London School of Hygiene and Tropical Medicine, London, United Kingdom 4Division of Infection and Immunity, University College London, London, United Kingdom Address for correspondence: Judith Bruer, FRCPath, MD, Division of Infection & Immunity, University College London, Cruciform Building, Gower Street, London WC1E 6BT, United Kingdom (e-mail: [email protected]). Neuroinfectious Disease; Guest Editor, Anna Cervantes-Arslanian, MD Semin Neurol 2019;39:xxx–xxx. Copyright © 2019 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: +1(212) 584-4662. DOI. ISSN 0271-8235. Herpesvirus Infections of the CNS/ Bharucha et al Herpesvirus Infections of the Central Nervous System Tehmina Bharucha, MRCP, MSc, DTM&H,1,2# Catherine F. Houlihan, MRCP, PhD, DTM&H FRCPath,3,4# Judith Breur, FRCPath, MD4 Dr. Judith Breur’s ORCHID is 0000-0002-6772-2855. #Joint First authors. Abstract There are over 200 herpes viruses species, of which 10 affect humans. Each of these 10 herpesviruses has a unique clinical syndrome, but common to all is their ability to cause infection and pathology in the central nervous system. In this article, we disucss the epidemiology, clinical presentation, diagnostic modalities, treatment, sequelae and avaibility of vaccination of each of the following herpesviruses: Herpes simplex virus 1 (HSV-1) and 2 (HSV-2), Varicella zoster virus (VZV), Human Cytomegalovirus (HCMV), Human Herpesvirus 6A (HHV-6A), 6B (HHV-6B) and 7 (HHV-7), Epstein Barr virus (EBV), Human Herpesvirus 8 (HHV-8), and Simian Herpesvirus B.
    [Show full text]